Clinical Stage Programs
Program
MOA
Indications
IND
Phase I
Phase II
Phase III
Rights
LM-108
Anti-CCR8 mAb
Solid tumors
Global available
LM-302
Anti-Claudin18.2 ADC
Gastrointestinal cancer
Turning Point （ex-China excl. Korea)
LM-305
Anti-GPRC5D ADC
Multiple Myeloma
AstraZeneca (Global)
LM-101
Anti-SIRPα mAb
Solid tumors & hematologic malignancies
Global available
Clinical Stage Programs
LM-108
Solid tumors
IND
Phase I
Phase II
Phase III
MOA
Anti-CCR8 mAb
Rights
Global available
LM-302
Gastrointestinal cancer
IND
Phase I
Phase II
Phase III
MOA
Anti-Claudin18.2 ADC
Rights
Turning Point （ex-China excl. Korea)
LM-305
Multiple Myeloma
IND
Phase I
Phase II
Phase III
MOA
Anti-GPRC5D ADC
Rights
AstraZeneca (Global)
LM-101
Solid tumors & hematologic malignancies
IND
Phase I
Phase II
Phase III
MOA
Anti-SIRPα mAb
Rights
Global available
Preclinical Stage Programs
Program
MOA
Indications
Discovery
PCC
IND-enabling
Rights
LM-001
ADC
Solid tumors
Global available
LM-002
ADC
Solid tumors
Global available
LM-003
ADC
Solid tumors
Global available
LM-004
ADC
Solid tumors
Global available
LM-005
ADC
Solid tumors
Global available
LM-006
ADC
Solid tumors
Global available
LM-007
Biparatopic ADC
Solid tumors
Global available
Clinical Stage Programs
LM-001
Solid tumors
Discovery
PCC
IND-enabling
MOA
ADC
Rights
Global available
LM-002
Solid tumors
Discovery
PCC
IND-enabling
MOA
ADC
Rights
Global available
LM-003
Solid tumors
Discovery
PCC
IND-enabling
MOA
ADC
Rights
Global available
LM-004
Solid tumors
Discovery
PCC
IND-enabling
MOA
ADC
Rights
Global available
LM-005
Solid tumors
Discovery
PCC
IND-enabling
MOA
ADC
Rights
Global available
LM-006
Solid tumors
Discovery
PCC
IND-enabling
MOA
ADC
Rights
Global available
LM-007
Solid tumors
Discovery
PCC
IND-enabling
MOA
Biparatopic ADC
Rights
Global available
